3-year follow-up from the transform trial: liso-cel is superior to soc in r/r dlbcl
Published 1 month ago • 50 plays • Length 3:59Download video MP4
Download video MP3
Similar videos
-
2:40
primary analysis of the phase iii transform study: liso-cel in second-line lbcl
-
1:43
extended follow-up of the alpine trial: superior outcomes with zanubrutinib in r/r cll/sll
-
5:49
magnetismm-3 extended follow up results: elranatamab monotherapy in r/r multiple myeloma
-
2:17
extended follow-up of the master trial
-
3:00
five-year follow-up of the captivate trial: ibrutinib retreatment in patients with cll
-
1:51
10-year follow-up of the lnh03-6b trial: outcomes of older patients with dlbcl treated with r-chop
-
2:01
updated follow-up results of the phase iii gaia/cll13 trial
-
45:21
builders #12 w/ tim lu (co-founder & ceo) & kanya rajangam (cmo/cdo) @ senti bio | bios
-
16:13
3mensio ct pre-case planning: valve-in-valve tavr in trifecta
-
20:26
3mensio ct pre-case planning: redo-tavr with prior sapien 3 (2 of 2)
-
2:58
long-term follow-up: phase ii study of apr-246 aza in tp53-mutated mds & aml
-
0:51
lessons from the aspire trial: three drug regimens as the new soc for relapsed mm
-
2:12
results from a phase i trial of tinostamustine in patients with r/r classical hl
-
0:42
upcoming trial updates in all
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:30
a phase i trial investigating a novel oral flt3 inhibitor, bmf-500, in flt3-mutant aml
-
2:16
phase i study of donor-derived γδ t cells as relapse prophylaxis post haplo/cy
-
3:54
cilta-cel as a potential new soc for r/r multiple myeloma: insights from the cartitude-4 trial
-
1:46
novel quadruplet and triplet front-line options for early r/r multiple myeloma
-
1:31
five-year follow-up of olutasidenib for idh1-mutated r/r aml
-
1:43
results from a three-year follow-up of venetoclax in patients with r/r al amyloidosis